Analyser av Prolight Diagnostics

In Q2, Prolight reported initial positive data from its ongoing whole blood study at St Thomas’ Hospital in London, showing equivalence betw...

Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk and securing the capital needed to final...

Key milestone for readiness Prolight has reported positive interim results from the ongoing patient blood study at St Thomas’ Hospital in Lo...

Strong insider commitment signals confidence As expected, Prolight has now announced a rights issue of SEK 100m to finance the development o...

Following the many recent grants, notices of allowance and intention to grant patents in Europe and the US, and the arrival of the first of ...

The recent acquisition of Norwegian point-of-care diagnostics platform SpinChip by bioMérieux for EUR 138 million underscores the growing in...

The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) system marks an important development mi...

Prolight continues to make progress with its proprietary Psyros platform, with a pre-validation study, including fresh blood samples from 12...

Supported by the latest troponin data generated from whole blood samples on the final commercial cartridge design, Prolight is now ready to ...

Prolight’s report for Q1’24 did not reveal any particular surprises.

Mangold Insight inleder bevakning av medicinteknik-bolaget Prolight Diagnostics med rekommendationen Köp.

There has been a somewhat mixed news flow from Prolight after the close of Q1’24.

There has been a somewhat mixed news flow from Prolight after the close of Q1’24.

With proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers even in whole blood, Prolight has...

Having already achieved proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers in low concent...